Skip to main content
TheraSphere Y-90 Glass Microspheres being administered to treat HCC.

TheraSphere™ Y-90 Glass Microspheres

Dosage and administration

Consensus on updated dosing recommendations for Y-90 Glass in HCC

Key updates from an international multidisciplinary working group include dosing recommendations below. These updates were driven by TheraSphere landmark studies and advancing Y-90 techniques to improve outcomes. See full publication or view the easy-to-navigate dosing recommendations resource.

  • Five clinical scenarios (curative and palliative intent) to facilitate standardized personalized treatment to improve outcomes
  • Targeted absorbed dose in selective treatment of ≥ 400 Gy for complete pathologic necrosis (radiation segmentectomy and modified radiation lobectomy)
  • Tumor absorbed dose of ≥ 205 Gy (> 250 Gy where possible) and normal absorbed dose in the perfused liver of ≤ 120 Gy in patients with ≥ 30% hepatic reserve 

Fight HCC* with optimized, high-potency Y-90 radiation

TheraSphere's unmatched radioactive concentration begins with its unique physical properties: Yttrium-90 (Y-90) is embedded within the glass matrix of each microsphere, enabling it to maintain a higher specific activity over a longer period of time.

TheraSphere Y-90 Glass Microsphere.

TheraSphere Y-90 Glass Microsphere

Radiation dose is embedded within the whole of the glass matrix, providing greater Y-90 loading capacity

Y-90 resin microsphere.

Y-90 Resin Microsphere

Radiation dose is only coated onto the surface area of a resin sphere,¹ limiting Y-90 loading capacity

Timeline showing TheraSphere Y-90 Glass Microspheres maintain a higher specific activity over time.

Personalized dosing. Simplified.

Simplicit90Y™ personalized dosimetry software, developed exclusively for TheraSphere Y-90 Glass Microspheres, allows you to enhance the consistency and efficiency of your dosing calculations. The software enables visualization of prospective dose distribution and assessment of the absorbed dose delivered to provide optimal ability to calculate confidently.

Double desktop monitor showing Simplicit90Y personalized dosimetry software for TheraSphere Y-90 Glass Microspheres.

TheraSphere is the only radiation therapy with Level 1 randomized data to demonstrate efficacy in large liver tumors (mean tumor size of 10.5 cm)⁵ while also validating reproducible dosimetry planning with Simplicit90Y™ Personalized Dosimetry Software.⁶


Glass delivers uniform dosing with low liver toxicity⁷,

A pre-clinical study confirmed there is a substantial difference in absorbed-dose homogeneity and decreased normal liver toxicity for treatments at or before 8 days post-calibration.8

Day 4: Heterogenous concentration of particles in normal tissue.
Day 12: More homogenous distribution of particles to normal tissue.

Reimbursement

Find coding and economic resources for health care practitioners and their partners.

References

  1. Grosser OS, Ruf J, Pethe A, Kupitz D, Wissel H, Benckert C, Pech M, Ricke J, Amthauer H. Urinary Excretion of Yttrium-90 after Radioembolization with Yttrium-90-Labeled Resin-based Microspheres. Health Phys. 2018 Jan;114(1):58-63. doi: 10.1097/HP.0000000000000734. PMID: 29049048.
  2. TheraSphere™ Y-90 Glass Microspheres IFU. Data on file
  3. Sirtex SIR-Spheres® FLEXdose Delivery Program https://www.sirtex.com/media/168730/flexdose-brochure_singlpg-apm-us-018-07-20-v3.pdf
  4. SIR-Spheres® Y-90 Resin Microspheres IFU https://www.sirtex.com/ media/169247/ssl-us-14-sir-spheres-microspheres-ifu-us.pdf 
  5. TheraSphere™ Y-90 Glass Microspheres DOSISPHERE-01 Study. Data on file.
  6. Lam, M., Garin, E., Maccauro, M. et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging (2022). https://doi.org/10.1007/s00259-022-05774-0.
  7. TheraSphere™ Y-90 Glass Microspheres TARGET Study. Data on file.
  8. Pasciak, A. S., Abiola, G., Liddell, R. P., Crookston, N., Besharati, S., Donahue, D., Thompson, R. E., Frey, E., Anders, R. A., Dreher, M. R., & Weiss, C. R. (2019). The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 816–827. https://doi.org/10.1007/s00259-019-04588-x.

*Refers to HCC or associated tumors

TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.